Chris Kell
Impact in
- Physiology top 5%
- Asthma and respiratory diseases
- Immunology and Allergy top 10%
- Allergic Rhinitis and Sensitization
Papers in
-
- IL-33, ST2, and ILC Pathways 3
- Immunotoxicology and immune responses 1
-
- Monoclonal and Polyclonal Antibodies Research 3
- Co-authors
- Dewei She (2 shared papers)Christopher Edward Brightling (1 shared paper)Néstor A. Molfino (1 shared paper)Raffaella Faggioni (1 shared paper)Chad K. Oh (1 shared paper)Robert McL. Niven (1 shared paper)Edward Piper (1 shared paper)Richard D. May (1 shared paper)
- Journals
- European Respiratory Journal (2 papers)ERJ Open Research (2 papers)Clinical Pharmacology & Therapeutics (1 paper)British Journal of Clinical Pharmacology (1 paper)Advances in Therapy (1 paper)
- Partner nations
- United KingdomSpainUnited States
In The Last Decade
Chris Kell
10 papers receiving 543 citations
Chris Kell's Hit Papers
Peers
Comparison fields: 5 of 39
- Physiology 303
- Immunology and Allergy 26
- Pulmonary and Respiratory Medicine 144
- Immunology 64
- Dermatology 26
Countries citing papers authored by Chris Kell
This map shows the geographic impact of Chris Kell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Kell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Kell more than expected).
Fields of papers citing papers by Chris Kell
This network shows the impact of papers produced by Chris Kell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Kell. The network helps show where Chris Kell may publish in the future.
Co-authors
The 25 scholars most cited alongside Chris Kell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 320 | |
| 2 | 2017 | 103 | |
| 3 | 2016 | 40 | |
| 4 | A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4 Hit paper breakdown → | 2025 | 38 |
| 5 | 2023 | 37 | |
| 6 | 2023 | 10 | |
| 7 | 2024 | 8 | |
| 8 | 2024 | 3 | |
| 9 | 2025 | 3 | |
| 10 | 2024 | 1 |
About Chris Kell
Chris Kell is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging, Physiology, Immunology and Allergy and Dermatology, having authored 10 papers that have together received 563 indexed citations. Recurring topics across this work include IL-33, ST2, and ILC Pathways (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Asthma and respiratory diseases (3 papers), Dermatology and Skin Diseases (1 paper), Immunotoxicology and immune responses (1 paper), Chronic Obstructive Pulmonary Disease (COPD) Research (1 paper), COVID-19 Clinical Research Studies (1 paper) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (1 paper). The work is most often cited by research in Physiology (303 citations), Immunology and Allergy (26 citations), Pulmonary and Respiratory Medicine (144 citations), Immunology (64 citations) and Dermatology (26 citations). Chris Kell has collaborated with scholars based in United Kingdom, Spain and United States. Frequent co-authors include Dewei She, Christopher Edward Brightling, Néstor A. Molfino, Raffaella Faggioni, Chad K. Oh, Robert McL. Niven, Edward Piper, Richard D. May, Gregory P. Geba and Joseph M. Parker. Their work appears in journals such as European Respiratory Journal, ERJ Open Research, Clinical Pharmacology & Therapeutics, British Journal of Clinical Pharmacology and Advances in Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.